Pay-For-Delay Antitrust Suits May Settle More Often After Jury Verdict For AstraZeneca
This article was originally published in The Pink Sheet Daily
Executive Summary
Jury finds AstraZeneca’s Nexium patent infringement settlement with Ranbaxy was not antitrust violation; direct purchasers and third party payers claimed agreement was worth nearly $1 billion.